Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD analyses continue to support ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial ...

Proton pump inhibitors (PPIs) do not appear to worsen kidney function compared with the histamine 2 receptor blocker ranitidine based on two measures, a large cohort study from Spain finds. In fact, ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...

Please provide your email address to receive an email when new articles are posted on . The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't ...